血清糖类抗原125和人附睾蛋白4在卵巢癌中的诊断价值

The application value of the serum HE4 and CA125 in the diagnosis of ovarian carcinoma

目的探讨人附睾上皮分泌蛋白4(HE4)和癌胚抗原125(CAl25)在妇科卵巢癌中的诊断价值。方法采用Cobas8000全自动电化学发光仪检测卵巢癌组、卵巢良性疾病组、其它腺癌组、健康对照组血清中的HE4和CA125的水平,并根据临床分期分别进行比较。结果卵巢癌组的血清HE4、CA125的结果明显高于其他各组,差异有统计学意义,(P<0.01)。卵巢良性疾病组、其它腺癌组、健康组两两比较,HE4和CA125表达水平差异没有统计学意义(P>0.05)。晚期(Ⅲ~Ⅳ)卵巢癌患者HE4和CA125的水平显著高于早期(Ⅰ~Ⅱ)患者(P<0.05)。血清HE4+CA125诊断卵巢癌的敏感性和特异性分别为94.32%、96.25%,HE4、CA125诊断卵巢癌的敏感性分别为81.23%、74.28%。特异性分别为85.11%、70.01%。结论血清标志物HE4和CA125联合检测是经济、有效的组合模式,有助于卵巢癌的鉴别诊断。

Objective To explore the application value of human epididymis secretory protein 4 （HE4） and Serum earbohydrate antigen （CA125） in the diagnosis of ovarian tumor. Methods Cobas8000 full- automation electro-chemiluminescence immunoassay （ECLIA） was used to detect the HE4 and CA125 levels in serum samples of ovarian cancer group, benign group, other adenocareinoma group and control group. And these groups were compared with each other according to the elinical stages. Results The levels of serum HE4 and CA125 in the ovarian cancer group were higher than those in other three groups, the differences were statistically significant （P〈0.01）.There were no statistieal signifieanees of HE4 and CA125 levels among benign group, other adenoeareinoma group and control group （P〉0.05）. The level of HE4 and CA125 was signifieantly higher in the patients with advanced ovarian cancer than patients in early stage （P〈O. 05）. The sensitivity and speeifieity of HE4 combined CA125 in the diagnosis of ovarian eaneer were 94.32% and 96.25%. The sensitivity of HE4 and CA125 respectively in the diagnosis of ovarian cancer was 81.23 and 74.28%, and the specificity was 85.11% and 70.01% respectively. Conclusions The combination of serum biomarkers （CA125 ＋ HE4 ） is economical and effeetive, which is helpful for the diagnosis of ovarian cancer.